Technology Appraisal Committee Meeting (Committee C)

Minutes: Confirmed

Date and Time: Tuesday 12 December 2017, 10:00 – 16:00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Dr Amanda Adler (Committee B) Present for all notes
2. Mr Michael Chambers Present for all notes
3. Mr David Chandler Present for all notes
4. Ms Gail Coster Present for all notes
5. Mr John Hampson Present for notes 9 to 29
6. Dr Rebecca Harmston (Committee D) Present for all notes
7. Dr Nigel Langford Present for all notes
8. Dr Andrea Manca Present for notes 1 to 16
9. Dr Richard Nicholas Present for all notes
10. Prof Stephen O’Brien Present for all notes
11. Ms Pam Rees (Committee A) Present for all notes
12. Prof Andrew Renehan Present for all notes
13. Prof Peter Selby Present for all notes
14. Prof Andrew Stevens, Chair Present for all notes
15. Prof Matt Stevenson Present for notes 1 to 16
16. Dr Paul Tappenden Present for notes 1 to 16
17. Prof Robert Walton Present for all notes
18. Dr Judith Wardle Present for all notes
19. Mr Nigel Westwood (Committee B) Present for all notes

In attendance:

Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes

Alex Filby Technical Advisor, National Institute for Health and Care Excellence Present for notes 17 to 29

Nicola Hay Technical Advisor, National Institute for Health and Care Excellence Present for notes 1 to 16

Anwar Jilani Technical Lead, National Institute for Health and Care Excellence Present for notes 1 to 16

Sana Khan Technical Lead, National Present for notes 17 to 29
Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of crizotinib for treating ROS1-positive advanced non-small-cell lung cancer and regorafenib for previously treated unresectable hepatocellular carcinoma.

2. The Chair informed the Committee of the non-public observers at this meeting: Leslie Hayes, Abitha Senthinathan, Nav Sumal and Laura Worthington.

3. Apologies were received from Prithwiraj Das, Kamal Balakrishnan and Derek Ward.

Appraisal of crizotinib for treating ROS1-positive advanced non-small-cell lung cancer [ID1098]

Part 1 – Open session
4. The Chair welcomed the invited experts: Janette Greenhalgh, Andrew Nicholson, Sanjay Popat, and Angela Stainthorpe to the meeting and they introduced themselves to the Committee.

5. The Chair welcomed company representatives from Pfizer to the meeting.

6. The Chair asked all Committee members to declare any relevant interests

6.1. Dr Amanda Adler, Mr Michael Chambers, Mr David Chandler, Ms Gail Coster, Mr John Hampson, Dr Rebecca Harmston, Dr Nigel Langford, Dr Richard Nicholas, Prof Stephen O'Brien, Ms Pam Rees, Prof Andrew Renehan, Prof Peter Selby, Prof Matt Stevenson, Dr Paul Tappenden, Prof Robert Walton, Dr Judith Wardle and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of crizotinib for treating ROS1-positive advanced non-small-cell lung cancer.

6.2. Dr Andrea Manca declared a financial, non-specific interest, stating that he had consulted on an advisory board for Pfizer in a different clinical area earlier in the year for which he received a fee. It was agreed that this declaration would not prevent Dr Andrea Manca from participating in this section of the meeting.

7. The Chair asked all NICE Staff to declare any relevant interests.

7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of crizotinib for treating ROS1-positive advanced non-small-cell lung cancer.

8. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

8.1. Sanjay Popat declared a non-specific financial interest, stating that he is a consultant to Pfizer and other companies with ROS1 and ALK therapies. It was agreed that this declaration would not prevent Sanjay Popat from participating in this section of the meeting.

8.2. Andrew Nicholson declared a non-specific, financial interest, stating that he had previously participated on an advisory board for Pfizer with unrestricted grants. It was agreed that this declaration would not prevent Andrew Nicholson from participating in this section of the meeting.

9. The Chair introduced the lead team, Mr John Hampson, Prof Matt Stevenson and Dr Judith Wardle who gave presentations on the clinical effectiveness and cost effectiveness of crizotinib for treating ROS1-positive advanced non-small-cell lung cancer.
10. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

11. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

12. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

13. Discussion on confidential information continued. This information was supplied by the company.

14. The Committee continued to discuss the clinical and cost effectiveness of crizotinib for treating ROS1-positive advanced non-small-cell lung cancer.

15.  

15.1. The committee decision was based on consensus.

16. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of regorafenib for previously treated unresectable hepatocellular carcinoma [ID991]

Part 1 – Open session

17. The Chair welcomed the invited experts: Dr Paul Tappenden and Prof Matt Stevenson to the meeting and they introduced themselves to the Committee.

18. The Chair welcomed company representatives from Bayer to the meeting.

19. The Chair asked all Committee members to declare any relevant interests.

19.1. Dr Amanda Adler, Prof Andrew Stevens, Mr Michael Chambers, Mr David Chandler, Ms Gail Coster, Mr John Hampson, Dr Rebecca Harmston, Dr Nigel Langford, Dr Richard Nicholas, Ms Pam Rees, Prof Andrew Renehan, Prof Peter Selby, Prof Robert Walton, Dr Judith Wardle and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of regorafenib for previously treated unresectable hepatocellular carcinoma.

19.2. It was noted that Committee members Professor Matt Stevenson and Dr Paul Tappenden were serving as ERG representatives and were therefore absent from the Committee.

20. The Chair asked all NICE Staff to declare any relevant interests.
20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of regorafenib for previously treated unresectable hepatocellular carcinoma

21. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of regorafenib for previously treated unresectable hepatocellular carcinoma

22. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

23. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

24. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

25. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

26. Discussion on confidential information continued. This information was supplied by the company.

27. The Committee continued to discuss the clinical and cost effectiveness of regorafenib for previously treated unresectable hepatocellular carcinoma

27.1. The committee decision was based on consensus.

28. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

29. Tuesday 23 January 2018 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT